Researchers at Penn University have successfully restored brain function to blind animals using gene therapy, showing promise for treating genetic retinal disease. The treatment, which involves introducing a working copy of the RPE65 gene into the retina, also revived responses in the visual cortex of the canine brain.
A new gene therapy clinical trial has reported promising results in improving motor function for patients with Parkinson's disease. The study found significant improvements in both the off-state and on-medication phases, with some patients showing impressive gains of up to 65 percent.
A Phase 1 study using an adeno-associated virus vector to deliver an inhibitory gene to the subthalamic nucleus demonstrated a lack of adverse events and statistically significant improvements in clinical symptoms and brain metabolism. The treated side showed notable improvement, with sustained benefits observed over 12 months.
A study published in The Lancet found that gene therapy can safely alleviate symptoms of Parkinson's disease, with significant improvements seen in movement and motor scores. The treatment involves injecting genetic information directly into brain cells, eliminating the need for indwelling hardware associated with deep-brain stimulation.
Scientists have discovered a way to transfer genes into diseased tissue of the human inner ear, aiming to restore hearing. The breakthrough could lead to the development of gene therapy compounds that produce new hair cells and restore hearing function in humans.
Researchers have discovered a new gene, LCA5, that causes inherited blindness in babies. The finding holds promise for future gene therapy treatments, which may restore vision by injecting genes into the eye.
Researchers successfully used gene therapy to block pain response in an animal model of neuropathic pain. The study involved delivering a genetically engineered herpes simplex virus to rats with the goal of activating the glycine receptor, which alleviated pain response. This breakthrough suggests that gene therapy may be effective for...
A new gene therapy has been shown to completely eliminate osteoarthritic pain and significantly reduce long-term joint damage in genetically engineered mice. The therapy works by increasing opioid receptors on nerve cells, making them more responsive to naturally occurring painkillers.
Researchers are developing gene therapies that can target and kill cancer cells, while also exploring the use of viruses and other natural systems to design new cancer treatments. Studies have shown promising results in animal models, including a novel gene therapy approach that eradicates aggressive prostate cancer.
Researchers at the University of Texas M. D. Anderson Cancer Center have successfully delivered a cancer-suppressing gene into tumors of stage 4 lung cancer patients via an intravenously administered lipid nanoparticle. The gene, FUS1, was found to be active in metastatic non-small cell lung cancer tumors.
Secondary analyses suggest that hormone therapy may have less risk of coronary heart disease (CHD) for women starting treatment close to menopause, while increasing risk is seen in older or farther-from-menopause women. Hormone therapy also increases stroke risk and breast cancer risk, even in younger women.
Researchers discovered a gene called Atp5a1 that, when mutated, reduces the incidence of polyps in mice. The mutation leads to decreased levels of Atp5a1 gene expression, which may provide insights into its potential role in human cancer.
Researchers used gene therapy to shut down a key gene responsible for inherited blindness, reducing mutated rhodopsin by 60%, in an effort to develop a treatment for retinitis pigmentosa. The technique may restore vision in affected individuals if successful.
Researchers at the University of Kentucky are exploring a novel gene therapy approach using DNA nanoparticles to deliver proteins beneficial to brain cells. This technology has shown potential in rescuing dormant brain cells, causing them to produce dopamine, and improving symptoms in animal models of Parkinson's disease.
A Phase I clinical trial suggests gene therapy is a safe treatment option for patients with poor circulation and blocked blood vessels in their lower limbs. The study found that almost half of patients reported complete resolution of chronic pain and over a quarter experienced complete healing of chronic wounds after one year.
Researchers have made significant breakthroughs with RNAi gene therapy, showing its effectiveness in shutting down viruses that cause diseases such as hepatitis and HIV in mice. With three human trials underway, the technique may be on the verge of widespread use for treating various human diseases.
A combination of bone marrow transplantation and gene therapy has greatly lengthened the lives of laboratory mice with Krabbé disease, a rapidly progressing neurodegenerative disorder also found in people. The dual therapy improved motor skills and increased lifespan by more than twice as long as untreated mice.
A study of the retinoblastoma gene found that it is essential for placenta development and may also contribute to miscarriages. The research used transgenic mice to disable the gene and observe its effects on embryonic development.
A clinical trial of gene transfer therapy for erectile dysfunction found significant and sustained improvements in patients who received a transfer gene called hMaxi-K. The therapy works by creating additional potassium channels in smooth muscle cells, relaxing the muscle and allowing blood flow required for an erection.
A new gene transfer therapy has shown promising results in treating erectile dysfunction (ED) and may also have potential benefits for overactive bladder, irritable bowel syndrome, and asthma. The therapy, which targets smooth muscle cells, was well-tolerated and safe in a small pilot study of 11 men.
Researchers found that continuous antiretroviral therapy significantly reduces the risk of opportunistic diseases and death compared to episodic therapy. The study also showed no reduction in serious side effects with continual ART.
Researchers have successfully tested a gene therapy to combat alpha-1 antitrypsin deficiency, a common hereditary disorder that causes lung and liver disease. The treatment showed no adverse effects and introduced the corrective gene into patients' blood, with some evidence of protein production.
Researchers at Massachusetts General Hospital found that proton beam radiation therapy achieved better tumor control for advanced adenoid cystic carcinoma of the cranial base compared to traditional radiation therapy. The study reported a 9% local recurrence rate, while traditional radiation resulted in over 70% local recurrence.
A study found that intravenous gene therapy protects normal tissue during whole-body radiation, leading to higher survival rates in mice. The therapy, administered before exposure, appeared to prevent the damaging effects of radiation, suggesting it is a viable delivery method for public protection in nuclear emergencies.
A Phase I study of novel gene therapy VRX496 for HIV treatment found five patients experienced decreases in viral load and stable or increased CD4 T cell counts after receiving the treatment. The trial also demonstrated the treatment's potential to restore normal immune function against other infections.
A study found that longer-term hormone therapy does not extend survival for high-risk prostate cancer patients. Instead, it may lead to a lesser degree of treatment side effects and improved quality of life.
Researchers developed a gene transfer method using the mutant form of apolipoprotein A-I (Apo A-I Milano) to treat vascular inflammation and plaque buildup. The study found that Apo A-I Milano gene transfer resulted in a 65% reduction in plaque buildup, compared to a 25% decrease with the normal HDL gene.
Researchers found that patients with advanced squamous cell carcinoma of the head and neck whose tumor samples over-expressed p53 protein were significantly more likely to respond to Advexin therapy than those with low p53 protein. The study suggests that p53 overexpression may be a predictive biomarker for Advexin efficacy.
University of Utah scientists reverse evolution by reconstructing a 530-million-year-old gene from two modern mouse genes. By combining key portions of Hoxa1 and Hoxb1, they effectively recreated a gene with the function that the original Hox1 performed more than 530 million years ago.
Researchers at St. Jude Children's Research Hospital developed a mouse model that explains why gene therapy treatment caused leukemia in some severe immune deficiency patients with XSCID. The study found that the disease itself makes mice susceptible to cancer caused by gene therapy, offering hope for safe treatment.
The study investigates how environmental and evolutionary factors influence genome structure and diversity through the proliferation of genes into multi-gene families. The research reveals that ecological factors play a significant role in shaping organismal complexity.
A study by Vahakn B. Shahinian and colleagues found that urologist input significantly influences the use of hormone therapy for prostate cancer patients, with up to 21% of variance attributed to their decisions. This suggests that urologists can be targeted for interventions to modify treatment recommendations.
Researchers at Einstein College of Medicine have observed a phenomenon where a gene plays a major role in organism development, displaying pulses of transcription that turn on and off at irregular intervals. This discovery could enable precise regulation of development by allowing genes to be turned on and off as needed, similar to a t...
Researchers found that injecting mice with gene therapy containing myostatin propeptide accelerated muscle regeneration and reduced fibrosis after injury. This approach could significantly reduce recovery time for athletes and lead to more complete functional recovery.
Researchers used gene therapy to treat ovarian cancer in a mouse model, achieving complete inhibition of tumor growth in some mice and significant inhibition in others. The treatment offers a promising alternative to harsh current treatments for this deadly disease.
Researchers at Stanford University School of Medicine have made significant progress in developing RNAi gene therapy, a promising approach to treating organ-wide diseases. However, they also encountered unexpected side effects, including liver toxicity in mice, which hindered their progress. Despite this setback, the team was able to o...
Researchers have successfully treated a chicken model of LCA1, a form of childhood blindness, using gene therapy. Six out of seven treated chicks developed sight, despite only a small percentage of receptor cells being infected by the virus. This study demonstrates the potential for gene therapy to treat this form of blindness in humans.
A study of 8,724 elderly women found that radiation therapy reduced breast cancer recurrence and mastectomies. Patients aged 70-79 years in good health gained the most benefit from radiation therapy.
In-vivo gene therapy has successfully restored immune function in three out of four dogs treated for XSCID. The treatment approach eliminates the need for ex-vivo cell manipulation and culture, potentially reducing adverse side effects and improving long-term efficacy.
A recent mouse study led by the Salk Institute has discovered that healthy copies of the IL2RG gene used in X-linked severe combined immune deficiency (X-SCID) gene therapy can promote cancer development. One-third of mice treated with the gene developed lymphoma later in life.
Researchers have made progress toward a new form of light-activated gene therapy for cartilage repair, which is safe and compatible with existing surgical techniques. The therapy uses UV light to target specific cells and promote tissue growth, offering hope for treating knee injuries and potentially other conditions.
Researchers have discovered a 100-kilobase segment of DNA missing from the agouti signaling protein (ASIP) gene in gibbons. The ASIP gene plays a role in lipid metabolism and energy homeostasis, but its deletion may have helped gibbons adapt to arboreal niches. Future studies will examine the physiological effects of this deletion.
The GeneDesign program guides the design of DNA segments with exacting specifications required for studying gene function and genetically engineering cells. It automatically diagnoses design flaws in the sequence of bases making up the gene, simplifying the creation of artificial genes.
Researchers at Northwestern University have developed a gene therapy that turns off the alpha-synuclein protein, a key player in Parkinson's disease. The therapy uses RNA interference to selectively disable the gene, leaving other genes unaffected, and has shown promising results in rat models.
A major gene therapy advance for treating Parkinson's disease has been funded by the Fox Foundation grant, with RheoGene Inc. developing a technology to manage gene expression. The therapy uses a patented small-molecule mediator to turn genes on or off, offering a potential solution to replacing lost dopamine in the brain.
Researchers used gene therapy to introduce a healthy copy of the dystrophin gene into mice with muscular dystrophy, repairing the entire muscle cell. The technique, developed by Michele Calos, has potential for long-term fixes for various genetic diseases.
Cedars-Sinai researchers have developed a new delivery system that can effectively regulate therapeutic gene expression, overcoming obstacles in bringing genetic therapies to humans. The system allows for the flexibility to turn gene expression on or off, even in the presence of an immune response, making it a critical tool for treatin...
The ESC has issued a policy statement on reperfusion therapy for STEMI treatment, highlighting the importance of early diagnosis and timely initiation of therapy. The statement recommends prioritizing primary PCI and thrombolytic treatment within three hours of symptom onset.
Researchers have developed a biocompatible polymer that briefly changes from liquid to gel at body temperature to block gene-bearing viruses from leaking into the bloodstream and harming other tissues. This method reduces misdirected virus dissemination by a factor of 100-1,000 times, solving the problem of toxic leakage in gene therapy.
Researchers found that exercise combined with gene therapy significantly extended the lifespan of mice with ALS, averaging 210 days, compared to 120 days in untreated mice. Early exercise initiation also improved outcomes, suggesting a potential strategy for slowing disease progression.
Researchers developed a gene therapy using adeno-associated virus (AAV-8) to deliver a normal copy of the delta-sarcoglycan gene to skeletal and cardiac muscle cells. The treatment showed remarkable improvements in muscle function, structure, and endurance in hamsters with muscular dystrophy.
A study of 869 women found that radiation therapy after surgery reduced breast cancer recurrence by almost 100%, with an overall survival rate of 97%. Radiation therapy also did not impact patients' quality of life or long-term survival rates.
Researchers found that gene therapy using manganese superoxide dismutase plasmid liposome (MnSOD-PL) protected healthy tissue from damage during and after radiation retreatment. The therapy significantly improved survival rates and reduced side effects in lung cancer patients.
Researchers discovered that KLF2 regulates embryonic globin genes and maturation of red blood cells in a mouse model, potentially paving the way for future gene therapies. The study highlights the importance of understanding gene regulation in blood disorders like sickle cell anemia and beta-thalassemia.
Researchers develop gene therapy that increases atrial natriuretic peptide production to control blood pressure without severely reducing it. The therapy successfully maintained healthy blood pressure levels for 125 days in mice.
A Yale University study found that early use of hormone therapy is linked to fewer wrinkles and firmer skin. The researchers compared 11 non-users with nine long-term hormone therapy users and found significant decreases in wrinkle severity and rigidity.
Researchers used genome synteny to study two closely related flower genes, AGAMOUS and PLENA, in Arabidopsis and Antirrhinum. They found that the genes originated from a single duplicated event around 125 million years ago.
Researchers at the University of Pittsburgh Medical Center have successfully treated animals with muscular dystrophy using a miniature gene and new systemic approach, demonstrating significant improvements in muscle function and longevity. The treatment involves delivering a mini-agrin gene via adeno-associated virus vectors, restoring...
Researchers developed a large brain tumor model and tested a genetically engineered virus delivering two proteins to the brain. The findings show that combined RAdTK and RAdFlt3L gene therapy eliminated glioblastoma multiforme in lab rats, increasing survival rates significantly.
Scientists at the University of Florida have developed a gene therapy that prevents blindness in mice with retinoschisis, a rare genetic disorder. The treatment involves injecting a healthy version of the human RS1 gene to prevent cyst formation and restore vision in affected eyes.